



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rosen et al.

Docket No.: PF112P1D2

Application No.: 10/023,584

Confirmation No.: 4809

Filed: December 21, 2001

Art Unit: 1647

For: Antibodies to Human Vascular Endothelial
Growth Factor 2 (As Amended)

Examiner: R. S. Landsman

**SIXTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references FX-GH listed on the attached Form PTO/SB/08.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

References FX-GH were previously listed as references AF-AM, FR, DW, and EB, respectively, on the Information Disclosure Statement filed by Applicants on December 21,

2001. The references were subsequently lined through by the Examiner and objected to as being incomplete citations. See Paper No. 102803, page 3.

Applicants therefore believe that no fee is required for this submission. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: April 26, 2004

Respectfully submitted,

By 

Melissa J. Pytel

Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road

Rockville, Maryland 20850

(301) 610-5764

MMW/MJP/ba



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/023,584-Conf. #4809
				Filing Date	December 21, 2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	R. S. Landsman
Sheet	1	of	1	Attorney Docket Number	PF112P1D2

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	FX	WO-99/46364	09-16-1999	Human Genome Sciences, Inc.		
	FY	WO-98/33917	06-08-1998	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.		
	FZ	WO-98-07832	02-26-1998	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.		
	GA	WO-96/39515	12-12-1996	Human Genome Sciences, Inc.		
	GB	WO-96/05856	02-29-1996	Human Genome Sciences, Inc.		
	GC	WO-95/24414	09-14-1995	Human Genome Sciences, Inc.		
	GD	WO-95/19985	07-27-1995	Human Genome Sciences, Inc.		
	GE	WO-92/14748	09-03-1992	American Cyanamid Co.		
	GF	ZA-9-403464	01-31-1996	Human Genome Sciences, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GG	LITWIN et al., "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129 (1995).	
	GH	WALSH et al., "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204:289-300 (1993).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--